{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:47:05Z","timestamp":1786682825532,"version":"build-2736575974"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.omtm.2022.09.010","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T11:48:42Z","timestamp":1664020122000},"page":"109-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"Qiushi","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva C.","family":"Vlaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon M.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"Stok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"van Helsdingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold G.","family":"Vulto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek P.","family":"van Til","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.W.M. Pim","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2022.09.010_bib1","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease. Lysosomal Storage Disorders","article-title":"Pompe disease: glycogen storage disease type II, acid \u03b1-glucosidase (acid maltase) deficiency | the online metabolic and molecular bases of inherited disease | OMMBID | McGraw-hill medical","author":"Reuser","year":"2018"},{"key":"10.1016\/j.omtm.2022.09.010_bib2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2022.09.010_bib3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtm.2022.09.010_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"Van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.omtm.2022.09.010_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nmd.2008.11.007","article-title":"Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease","volume":"19","author":"Van der Beek","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2022.09.010_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"Van Der Beek","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2022.09.010_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2022.09.010_bib8","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.omtm.2022.09.010_bib9","first-page":"91","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtm.2022.09.010_bib10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib11","first-page":"952","article-title":"Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years","volume":"259","author":"Angelini","year":"2012","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtm.2022.09.010_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2022.09.010_bib13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.09.010_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","article-title":"Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years","volume":"117","author":"Stepien","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2022.09.010_bib15","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.09.010_bib16","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.09.010_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.09.010_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.omtm.2022.09.010_bib19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10545-010-9206-3","article-title":"Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience","volume":"33","author":"Chakrapani","year":"2010","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.09.010_bib20","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2018.04.025","article-title":"Therapeutic benefit of autophagy modulation in pompe disease","volume":"26","author":"Lim","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2022.09.010_bib22","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.4161\/auto.21691","article-title":"Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients","volume":"8","author":"Nascimbeni","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.omtm.2022.09.010_bib23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.09.010_bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.omtm.2022.09.010_bib26","first-page":"98","article-title":"Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state","volume":"9","author":"Matsuoka","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2022.09.010_bib27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1212\/WNL.0000000000002523","article-title":"Cognitive decline in classic infantile Pompe disease: an underacknowledged challenge","volume":"86","author":"Ebbink","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.09.010_bib28","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.0b013e31828b8af0","article-title":"Cognitive outcome of patients with classic infantile pompe disease receiving enzyme therapy","volume":"80","author":"Spiridigliozzi","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.09.010_bib29","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1212\/WNL.0b013e3182553c11","article-title":"Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy","volume":"78","author":"Ebbink","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.09.010_bib30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10545-010-9209-0","article-title":"CRIM-negative infantile Pompe disease: 42-month treatment outcome","volume":"33","author":"Rohrbach","year":"2010","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2022.09.010_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1203\/01.pdr.0000233014.84318.4e","article-title":"Brain development in infantile-onset pompe disease treated by enzyme replacement therapy","volume":"60","author":"Chien","year":"2006","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.omtm.2022.09.010_bib32","doi-asserted-by":"crossref","first-page":"100789","DOI":"10.1016\/j.isci.2019.100789","article-title":"Sharpening the molecular scissors: advances in gene-editing Technology","volume":"23","author":"Broeders","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.omtm.2022.09.010_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JND-190426","article-title":"Advancements in AAV-mediated gene therapy for pompe disease","volume":"7","author":"Salabarria","year":"2020","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2022.09.010_bib34","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2012.140","article-title":"Gene therapy approaches for lysosomal storage disease: next-generation treatment","volume":"23","author":"Byrne","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/atm.2019.05.02","article-title":"Liver depot gene therapy for Pompe disease","volume":"7","author":"Kishnani","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib36","doi-asserted-by":"crossref","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib37","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.ymthe.2020.05.025","article-title":"Rescue of advanced pompe disease in mice with hepatic expression of secretable Acid \u03b1-glucosidase","volume":"28","author":"Cagin","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib38","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1038\/s41467-021-26744-4","article-title":"Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates","volume":"12","author":"Costa-Verdera","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2022.09.010_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.09.010_bib40","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ymthe.2017.03.025","article-title":"Hematopoietic stem cell gene therapy for storage disease: current and new indications","volume":"25","author":"Biffi","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","article-title":"Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives","volume":"118","author":"Solomon","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtm.2022.09.010_bib42","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.omtm.2022.09.010_bib43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41591-018-0301-6","article-title":"Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent \u00df-thalassemia","volume":"25","author":"Marktel","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib44","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib45","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib46","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2022.09.010_bib47","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.09.010_bib48","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/B978-0-12-386509-0.00010-7","article-title":"Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy","author":"Cartier","year":"2012"},{"key":"10.1016\/j.omtm.2022.09.010_bib49","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood-2009-11-252874","article-title":"Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype","volume":"115","author":"van Til","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.09.010_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jgm.1305","article-title":"Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of \u03b1-glucosidase in Pompe disease","volume":"11","author":"Douillard-Guilloux","year":"2009","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib51","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.omtm.2020.04.023","article-title":"Lentiviral hematopoietic stem cell gene therapy corrects murine pompe disease","volume":"17","author":"Stok","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.09.010_bib52","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib53","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ymthe.2017.12.022","article-title":"Gene therapy for adenosine deaminase deficiency: a comprehensive evaluation of short- and medium-term safety","volume":"26","author":"Cicalese","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib54","doi-asserted-by":"crossref","first-page":"335ra57","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"de Ravin","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib55","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.omtm.2022.09.010_bib56","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with wiskott-aldrich syndrome","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.09.010_bib57","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1074\/jbc.274.2.1164","article-title":"The rate of internalization of the mannose 6-phosphate\/insulin-like growth factor II receptor is enhanced by multivalent ligand binding","volume":"274","author":"York","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2022.09.010_bib58","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid\u03b1-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2022.09.010_bib59","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1089\/hum.2021.053","article-title":"Long-term follow-up of hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"32","author":"Bougn\u00e8res","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib60","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.09.010_bib61","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood.2020010260","article-title":"Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency","volume":"138","author":"Reinhardt","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.09.010_bib62","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4161\/auto.2984","article-title":"Autophagy and lysosomes in Pompe disease","volume":"2","author":"Fukuda","year":"2006","journal-title":"Autophagy"},{"key":"10.1016\/j.omtm.2022.09.010_bib63","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1034\/j.1601-183X.2003.00028.x","article-title":"Differences among eight inbred strains of mice in motor ability and motor learning on a rotorod","volume":"2","author":"McFadyen","year":"2003","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.omtm.2022.09.010_bib64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1212\/WNL.23.1.95","article-title":"The spectrum and diagnosis of acid maltase deficiency","volume":"23","author":"Engel","year":"1973","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.09.010_bib65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/hmg\/7.1.53","article-title":"Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease","volume":"7","author":"Bijvoet","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2022.09.010_bib66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4161\/auto.5.1.7293","article-title":"When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease","volume":"5","author":"Raben","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.omtm.2022.09.010_bib67","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/NEN.0b013e3181815994","article-title":"Temporal neuropathologic and behavioral phenotype of 6 neo\/6 neo Pompe pisease mice","volume":"67","author":"Sidman","year":"2008","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.omtm.2022.09.010_bib68","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fnins.2015.00417","article-title":"Neuroinflammatory paradigms in lysosomal storage diseases","volume":"9","author":"Bosch","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtm.2022.09.010_bib69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ceb.2015.02.004","article-title":"Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system","volume":"32","author":"Hol","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.omtm.2022.09.010_bib70","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1073858411423441","article-title":"Structural remodeling of astrocytes in the injured CNS","volume":"18","author":"Sun","year":"2012","journal-title":"Neuroscientist"},{"key":"10.1016\/j.omtm.2022.09.010_bib71","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/nn1997","article-title":"Microglia: active sensor and versatile effector cells in the normal and pathologic brain","volume":"10","author":"Hanisch","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtm.2022.09.010_bib72","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","article-title":"Microglia: a sensor for pathological events in the CNS","volume":"19","author":"Kreutzberg","year":"1996","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.omtm.2022.09.010_bib73","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-017-0693-2","article-title":"A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease","volume":"12","author":"Byrne","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2022.09.010_bib74","series-title":"JIMD Reports","first-page":"45","article-title":"Postmortem findings and clinical correlates in individuals with infantile-Onset pompe disease","author":"Pena","year":"2015"},{"key":"10.1016\/j.omtm.2022.09.010_bib75","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab. Invest."},{"key":"10.1016\/j.omtm.2022.09.010_bib76","first-page":"379","article-title":"Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings","volume":"27","author":"Teng","year":"2004","journal-title":"Chang Gung Med. J."},{"key":"10.1016\/j.omtm.2022.09.010_bib77","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1212\/WNL.57.5.906","article-title":"Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2","volume":"57","author":"Martini","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.09.010_bib78","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00687878","article-title":"Pompe\u2019s disease: an inborn lysosomal disorder with storage of glycogen - a study of brain and striated muscle","volume":"23","author":"Martin","year":"1973","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omtm.2022.09.010_bib79","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00005072-197107000-00008","article-title":"Nervous system in Pompe\u2019s disease","volume":"30","author":"Gambetti","year":"1971","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.omtm.2022.09.010_bib80","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0002-9343(68)90160-5","article-title":"Type II glycogenosis. Biochemical and electron microscopic study","volume":"44","author":"Garancis","year":"1968","journal-title":"Am. J. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib81","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00005072-196501000-00008","article-title":"Pompe\u2019s disease (diffuse glycogenosis) with neuronal storage","volume":"24","author":"Mancall","year":"1965","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.omtm.2022.09.010_bib82","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jnnp.26.5.422","article-title":"Neuropathological and neurochemical aspects of generalized glycogen storage disease","volume":"26","author":"Crome","year":"1963","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omtm.2022.09.010_bib83","doi-asserted-by":"crossref","first-page":"e51031","DOI":"10.7554\/eLife.51031","article-title":"Impaired lysosomal acidification triggers iron deficiency and inflammation in\u00a0vivo","volume":"8","author":"Yambire","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.omtm.2022.09.010_bib84","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.1205858109","article-title":"Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation","volume":"109","author":"Capotondo","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2022.09.010_bib85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/glia.21104","article-title":"Microglia in the CNS: immigrants from another world","volume":"59","author":"Prinz","year":"2011","journal-title":"Glia"},{"key":"10.1016\/j.omtm.2022.09.010_bib86","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/nn2015","article-title":"Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions","volume":"10","author":"Mildner","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtm.2022.09.010_bib87","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib88","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ana.20807","article-title":"Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease","volume":"59","author":"Fukuda","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2022.09.010_bib89","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/emmm.201202176","article-title":"Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease","volume":"5","author":"Spampanato","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib90","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/nan.12214","article-title":"Impaired autophagy affects acid \u03b1-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II","volume":"41","author":"Nascimbeni","year":"2015","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.omtm.2022.09.010_bib91","doi-asserted-by":"crossref","first-page":"279","DOI":"10.21037\/atm.2019.03.51","article-title":"Pros and cons of different ways to address dysfunctional autophagy in Pompe disease","volume":"7","author":"Lim","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib92","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","article-title":"Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY Study","volume":"119","author":"van der Ploeg","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2022.09.010_bib93","doi-asserted-by":"crossref","first-page":"e8730","DOI":"10.15252\/emmm.201708730","article-title":"Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms","volume":"10","author":"Gleitz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib94","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41591-018-0195-3","article-title":"Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans","volume":"24","author":"Scala","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41591-021-01554-9","article-title":"Lentiviral globin gene therapy with reduced-intensity conditioning in adults with \u03b2-thalassemia: a phase 1 trial","volume":"28","author":"Boulad","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib96","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41591-021-01650-w","article-title":"Long-term outcomes of lentiviral gene therapy for the \u03b2-hemoglobinopathies: the HGB-205 trial","volume":"28","author":"Magrin","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib97","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.09.010_bib98","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/hum.2016.037","article-title":"Cell and gene therapy for the beta-thalassemias: advances and prospects","volume":"27","author":"Mansilla-Soto","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib99","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood.2019000949","article-title":"Lentiviral and genome-editing strategies for the treatment of \u03b2-hemoglobinopathies","volume":"134","author":"Magrin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.09.010_bib100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/hum.2012.203","article-title":"Mechanisms of retroviral integration and mutagenesis","volume":"24","author":"Cavazza","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib101","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/cells10051077","article-title":"Combining mobilizing agents with busulfan to reduce chemotherapy-based conditioning for hematopoietic stem cell transplantation","volume":"10","author":"Garcia-Perez","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omtm.2022.09.010_bib102","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/jth.13800","article-title":"Immune tolerance induced by platelet-targeted Factor VIII gene therapy in hemophilia A mice is CD4 T\u00a0cell-mediated","volume":"15","author":"Chen","year":"2017","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.omtm.2022.09.010_bib103","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.ymthe.2019.05.022","article-title":"Busulfan combined with immunosuppression allows efficient engraftment of gene-modified cells in a rhesus macaque model","volume":"27","author":"Uchida","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib104","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/mt.2009.312","article-title":"Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates","volume":"18","author":"Fontanellas","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.09.010_bib105","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omtm.2022.09.010_bib106","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40478-018-0620-3","article-title":"Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease","volume":"6","author":"Schaaf","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.omtm.2022.09.010_bib107","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<416::AID-PATH445>3.0.CO;2-6","article-title":"Pathological features of glycogen storage disease type II highlighted in the knockout mouse model","volume":"189","author":"Bijvoet","year":"1999","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.omtm.2022.09.010_bib108","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1152\/physiolgenomics.2001.5.4.171","article-title":"Cardiac remodeling and contractile function in acid \u03b1-glucosidase knockout mice","volume":"5","author":"Kamphoven","year":"2001","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.omtm.2022.09.010_bib109","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2022.09.010_bib110","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in\u00a0vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2022.09.010_bib111","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1083\/jcb.125.6.1275","article-title":"Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy","volume":"125","author":"Rando","year":"1994","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omtm.2022.09.010_bib112","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41431-020-00751-3","article-title":"A generic assay for the identification of splicing variants that induce nonsense-mediated decay in Pompe disease","volume":"29","author":"Bergsma","year":"2021","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2022.09.010_bib113","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/humu.22705","article-title":"Identification and characterization of aberrant GAA Pre-mRNA splicing in pompe disease using a generic approach","volume":"36","author":"Bergsma","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtm.2022.09.010_bib114","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40478-015-0243-x","article-title":"Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease","volume":"3","author":"Schaaf","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.omtm.2022.09.010_bib115","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mus.10381","article-title":"Morphological changes in muscle tissue of patients with infantile Pompe\u2019s disease receiving enzyme replacement therapy","volume":"27","author":"Winkel","year":"2003","journal-title":"Muscle Nerve"}],"container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122001358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122001358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:29:05Z","timestamp":1762421345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050122001358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":115,"alternative-id":["S2329050122001358"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2022.09.010","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2022.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}